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Abstract
Introduction: Sex cord-stromal tumors of the ovary are uncommon. They behave unpredictably and often have a
late recurrence, making counseling, management, and prediction of prognosis challenging.
Case presentation: A 52-year-old Moroccan woman with an sex cord-stromal tumors underwent a bilateral
oophorectomy. The histology was unusual but was likely to be a luteinized thecoma with suspicious features for
invasion. Seven years later, after a gastrointestinal bleed, a metastasis within the small bowel mucosa was detected.
This represents probable isolated hematogenous or lymphatic spread, which is highly unusual, especially in the
absence of concurrent peritoneal disease.
Conclusions: To the best of our knowledge, this is the second reported case of an sex cord-stromal tumors
recurring in small bowel mucosa and mimicking a primary colorectal tumor. This highlights the diverse nature and
behavior of these tumors.
Introduction
Sex cord-stromal tumors (SCSTs) of the ovary are
uncommon neoplasms that account for 5% to 8% of all
ovarian malignancies [1]. Their histopathologic appear-
ance and malignant potential are highly variable, making
the optimum treatment of these tumors difficult to
establish. The group includes granulosa-stromal tumors,
fibroma-thecoma, Sertoli-str o m a lc e l lt u m o r s ,s t e r o i d
cell tumors, and SCSTs of mixed or unclassifiable type.
The unpredictable behavior and often late recurrence of
these tumors make counseling of patients about subse-
quent management and prognosis a major challenge.
We present an unusual case of an SCST that, in keeping
with the variable behavior of these tumors, was difficult
to classify.
Case presentation
We report the case of a 52-year-old Moroccan woman
who had been menopausal for 14 years. She presented
with a lower abdominal pain. She had not experienced
any postmenopausal bleeding and had no bowel or urin-
ary symptoms. She was a nonsmoker. She had no other
significant medical history and no sign of virilization.
An examination revealed a smooth cystic mass posterior
to the uterus. A transvaginal and transabdominal pelvic
ultrasound demonstrated a 9 × 3.7 cm heterogeneous
mass in her left adnexa. No vascular flow or ascites was
seen, the ovaries did not appear to be separate from the
mass. A chest X-ray was normal. Serum CA-125 level
was 6 IU/mL. Renal, liver, and hematologic parameters
were all in normal range. At laparotomy, a large torted
left ovarian cyst with small bowel adhesions to its sur-
face was discovered. Her right ovary appeared normal
but was adherent to her small bowel; her uterus was
normal. Her liver and omentum appeared normal, and
there was no pelvic or abdominal lymphadenopathy.
There was a small amount of ascites that was sent for
cytology. An oophorectomy was performed with no
macroscopic residual disease. An omental biopsy was
taken. The histology showed a tumor of sex cord-stro-
m a lt y p ei nt h eo v a r yb u tt h et u m o rw a sd i f f i c u l tt o
classify further (Figure 1). The main left component
comprised dense spindle cells interspersed with small
groups of cells with a prominent eosinophilic cytoplasm.
Crystals of Reinke, a marker of Leydig cell differentia-
tion, were not identified within the majority of these
cells, but there was a group at the hilum at the edge of
the tumor. In the absence of unequivocal crystals of
Reinke, the tumor was reported as a luteinized thecoma.
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tumor could not be considered benign and we suspected
malignancy. The ascites was free of abnormal cells. No
vascular invasion was identified. Immunohistochemistry
showed that the tumor was positive for inhibin and
v i m e n t i n .T h e r ew a sn oe v i d e n c eo fm e t a s t a s i si nt h e
other specimens received. Our patient made an uncom-
plicated recovery and was followed up every six months
for five years before being discharged. Soon, she pre-
sented with a fresh rectal bleeding and melena. She had
not experienced any weight loss or change in bowel
habit and was otherwise asymptomatic. The initial
examination was unremarkable. Upper and lower gastro-
intestinal endoscopies were performed, and, with the
exception of mild gastritis, no abnormality was detected.
A computed tomography scan of the abdomen and pel-
vis confirmed the mass to be within a loop of small
bowel with some dilatation of the bowel proximal to
this (Figure 2). During laparotomy, a soft intraluminal
mass within her ileum was identified. There was no
defect in the serosa of the bowel and no evidence of
peritoneal or pelvic deposits. A recurrence of the ovar-
ian tumor seemed unlikely. Histology of the lesion
showed appearances very similar to those of the pre-
vious ovarian tumor except that the endocrine compo-
nent was more prominent (Figure 3). The gross
appearances were very unusual in that there was trans-
mural involvement of the small bowel and an ulcerated
polypoid mass protruded into the lumen. The mass was
a rare metastatic recurrence of an SCST and appeared
to be isolated within the small bowel. Our patient
underwent three cycles of a BEP chemotherapy regimen,
which consists of bleomycin, etoposide, and cisplatin.
She has remained asymptomatic with no clinical
evidence of recurrence 27 months after the small bowel
resection.
Discussion
SCSTs vary greatly in prognosis and behavior, depend-
ing on the subtype. Therefore, deciding on methods of
management for recurrence can be difficult, especially
when the tumor is at an unusual site, as in this case.
Since disseminated spread is the most common mode of
metastasis in ovarian cancer, the gastrointestinal tract is
frequently involved. In some advanced cases, determin-
ing whether the origin of the tumor is bowel or ovarian
Figure 1 The histology from the primary ovarian sex cord-
stromal type tumor, which was difficult to classify. In the
absence of unequivocal crystals of Reinke, the tumor was classified
as a luteinized thecoma. Magnification × 200.
Figure 2 A computed tomography scan demonstrating a
fibroid uterus (A), anterior to the uterus is an 8x 6x 6 cm mass (B).
Figure 3 The histology from the small bowel tumor shows the
same histologic features as the primary ovarian lesion. Normal
small bowel villi are also seen. Magnification × 20.
El Mehdi et al. Journal of Medical Case Reports 2011, 5:350
http://www.jmedicalcasereports.com/content/5/1/350
Page 2 of 4can be difficult. The use of immunohistochemical mar-
kers such as CK7 and CK20 can assist in the differentia-
tion. The question of tumor origin did not present a
problem with this case as the histologic morphology
clearly demonstrated a recurrent SCST as opposed to an
adenocarcinoma, which could be of ovarian or colonic
origin. The majority of gastrointestinal recurrences from
ovarian tumors occur via direct transcoelomic spread
and invasion of the serosal surface in a centripetal direc-
tion. Rose and colleagues [2] demonstrated metastasis
relating to small bowel in 43% of autopsies performed
for ovarian cancer. However, it is likely that these
tumors have mainly serosal involvement and there were
n oS C S T si nt h i ss e r i e s[ 2 ] .M o s tt u m o r si n v o l v i n gt h e
mucosa of the bowel will show evidence of associated
serosal involvement. Reed and colleagues [3], in a review
of 77 autopsy records of ovarian cancer, discovered
bowel serosal involvement in 86% and mucosal involve-
ment in 36%. The present case is unusual in that the
metastasis appears to have arisen in the mucosa alone,
suggesting hematogenous or lymphatic spread. It has
been suggested that this spread occurs in epithelial ovar-
ian tumors along bowel wall lymphatic channels, dis-
playing a “buckshot” distribution in which multiple
separate foci are seen along a length of bowel mucosa.
This lymphatic spread occurs only when there is a high
level of intraperitoneal disease, which was not seen in
our patient [4]. Some SCSTs are considered to be of
low malignant potential, having a low proliferation rate
similar to that of borderline tumors of the ovary.
Because these SCSTs are slow-growing, they tend to
present at an earlier stage compared with epithelial
tumors and have an excellent prognosis; overall five-
year survival is 79%. Recurrence and metastasis are rare
and often late. More than 50% of recurrences occur
after more than five years, and 25% occur after 10 years
[5]. Others such as thecomas and fibromas generally
behave in a benign fashion, although features such as
mitotic rate, hemorrhage, and necrosis should be
regarded with caution as these recurrences may be bet-
ter regarded as fibrosarcomas. Both luteinized thecomas
and stromal Leydig cell tumors are usually regarded as
benign, but in our patient, there were worrying features
that were identified on the initial histology. Zhang and
colleagues [6] reported a series of 50 ovarian stromal
tumors in which luteinized or Leydig cells were present,
and four appeared malignant histologically. One patient
died early on, one was alive and well at five years, and
there was insufficient follow-up on the other two. The
authors state that luteinized thecomas and stromal Ley-
dig cells are distinguished only by the presence of crys-
tals of Reinke and that, owing to the difficulty in
identifying these structures; some luteinized thecomas
may well be unrecognized stromal Leydig cell tumors
[6]. Virilization may encourage to search crystals of
Reinke. Very few cases of stromal Leydig cell tumors
have been reported. In addition to the series of Zhang
and colleagues [6], two have been reported in young
women [7,8]. Surgical intervention is generally adopted
as the primary mode of treatment; this is often conser-
vative in young women wishing to retain their fertility.
Age, large tumor size, lymph node involvement, and
residual disease are all predictors of poor prognosis [5].
Although surgery is likely to remain the foundation for
treatment of SCSTs, chemotherapy has been used as an
adjunct in particular cases. Various authors have used
chemotherapy in selected cases with advanced stage, sig-
nificant residual disease, metastasis, or recurrence.
Although it is likely that chemotherapy provides
improved survival in such cases, the optimum regimen
is still unclear. As SCSTs are variable in their histologic
appearance, many chemotherapy regimens are assessed
by using the most common subgroup, the granulosa cell
tumor, and the findings are extrapolated to all SCSTs.
In addition, owing to the indolent nature of these
tumors, long-term follow-up of any proposed treatment
is needed to observe the full effects. Hence, optimizing
chemotherapy treatment in these cases is a challenge. A
number of regimens - including vincristine, doxorubicin,
and cyclophosphamide; BEP; and, most recently, taxanes
(paclitaxel or docetaxel) - have been used in the past
[9]. A Gynecologic Oncology Group trial used BEP in
the treatment of incompletely resected stage II to IV or
recurrent SCSTs and found that 69% of primary
advanced tumors and 51% of recurrences remained pro-
gression-free following treatment, although there were
problems of bleomycin-related pulmonary toxicity in a
minority of cases [10]. The use of taxanes with or with-
out platinum has been shown to be as effective as BEP
with regard to disease-free survival and overall survival.
The taxane group experienced less major toxicity (14%
mainly hematologic) compared with the BEP group
(24% mainly pulmonary fibrosis or neutropenia). It
should be noted that, in all of the studies mentioned
above, the majority of tumors were adult granulosa cell
tumors and so the findings may not be directly applic-
able to other SCSTs.
Conclusions
This report further highlights the diverse nature and
behavior of this group of tumors. This case demon-
strates the difficulty in adopting an evidence-based
approach to the treatment and follow-up in these rare
cases. The need for careful discussion with the patient
about additional treatment, if any, is of paramount
importance.
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Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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